The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

The greater part of third quarter earnings results are in the rearview mirror. So far, the Q3 earnings season is off to a ...

The Commerce Department is considering changes to a Biden-era plan to connect millions of households to high-speed internet, The Wall Street Journal reported. Trump wants Europe to spend more on ...

The healthcare sector is heterogeneous, with a wide dispersion in returns between the best- and worst-performing stocks. Active management can pay off. Occidental rises ahead of earnings, Delta sinks ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

After a generation of stagnation, interest in U.S. nuclear energy is sky high, thanks to artificial intelligence’s voracious ...